In this episode, we dive into the transformational testimonial of Cesar Marin’s experience with microdosing. Once a CNN TV producer, and now a full time advocate for the power of intentional microdosing, Cesar shares with us his journey and how it helped transform his life.
Bob Parsons is an American entrepreneur and a Marine Corps…
![MAPS Phase 3 MDMA To Treat PTSD Trial Results: WOW [GREAT News For NUMI, MindMed, MYCO & Atai ]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-72-600x338.jpeg)
MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.
Also, there were 0 cases of serious adverse side effects in the MDMA group.
So which companies will be the largest benefactors of these results?
Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently
2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.
3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.
4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.
5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.
Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
Link to Numinus (NUMI): https://numinus.ca/
Link to Atai Life Sceinces : https://www.atai.life/
Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Clinical trials :
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #NUMIStock
CEO of Entheon Biomedical, Timothy Ko, discusses how the company plans to utilize the psychedelic compound, DMT, to treat a variety of addictions.
In this episode, we’re covering what is microdosing and its purported benefits. You will learn how to microdose magic mushrooms. How to microdose psychedelics.
Microdosing is the practice of taking a small dose of a drug, in our case psilocybin, the main active ingredient in magic mushrooms. The dose is small enough that it won’t cause any perceptual changes, meaning you won’t have any hallucinations or even feel high.
This will allow you to continue to go to school, work, or get more comfortable in social settings.
According to thousands upon thousands of anecdotal stories over decades, microdosing psilocybin is purported to:
– Improve your creativity;
– Help you enter states of flow, also known as “being in the zone” or entering a mental state of total energized concentration;
– Help alleviate feelings of stress and anxiety;
– Improve focus and concentration;
– Improves relational awareness and;
– Speeds your reflexes.
We have to rely on anecdotal evidence unfortunately, because until recently, very little scientific study has been done on the subject of microdosing, though that is starting to change with many clinical studies underway.
Despite a lack of hard scientific data, the practice is sworn upon by many in high pace environments, such as Silicon Valley. A couple famous examples of microdosers include: Joe Rogan and Steve Jobs, though for the later it was more LSD microdosing.
Let me know in the comments if you want to see a video on LSD microdosing in the future.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MicrodosingMushrooms #Microdosing #MagicMushrooms
In today’s episode, we discuss healing traumatic brain injury, also know as (TBI) with two times Stanley Cup Champion Daniel Carcillo, Founder and CEO of Wesana Health (CNSX: WESA | OTC: WSNAF)
For More Information on Wesana Health, visit:
https://www.wesanahealth.com/
Follow Wesana on Social Media:
Twitter: @wesanahealth
Instagram: @wesanahealth
Facebook: @wesanahealth
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
This video was conducted on behalf of Wesana Health, and was funded by Gold Standard Media LLC and/or affiliates. For our full disclaimer, please visit: https://portal.goldstandardir.com/disclaimer/WSNAF-85
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#WesanaHealth #WESASttock #Psychedelicstocks
In this episode, Psychedelic Spotlights, Director of Content, Jill Ettinger sits down with Chief Executive Officer, Director, and Co-Founder of Novamind, Yaron Conforti.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
